Literature DB >> 3654606

Existence of endogenous inhibitors of platelet-activating factor (PAF) with PAF in rat uterus.

R Nakayama1, K Yasuda, K Saito.   

Abstract

Two kinds of phospholipids in normal rat uterus were found to inhibit the aggregation of washed rabbit platelets induced by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (alkylacetyl-GPC) and were named Inhibitor I and Inhibitor II and identified by mass spectrometry. Inhibitor I was a mixture of 1-acyl (16:0, 18:0, 18:1, 18:2, and 20:4)-2-lyso-sn-glycero-3-phosphocholine (acyllyso-GPC) and 1-alkyl (16:0, 18:0, and 18:1)-2-lyso-sn-glycero-3-phosphocholine (alkyllyso-GPC). 16:0 acyllyso-GPC was the most inhibitory, followed by 18:1, 18:2, 20:4, and 18:0 acyllyso-GPCs and 16:0 alkyllyso-GPC. Their IC50 values were in the range of 1-4 X 10(-5) M against the platelet aggregation induced by 1 X 10(-10) M 16:0 alkylacetyl-GPC, indicating that they were about 100 times weaker inhibitors than CV-3988. Inhibitor II was a mixture of N-acyl sphing-4-enyl phosphocholine (18:1/18:0, 18:1/20:0, 18:1/24:0, and 18:1/24:2). The most inhibitory of these components were 18:1/20:0 and 18:1/24:0, followed by 18:1/24:2 and 18:1/18:0, and their IC50 values were in the range of 4-5 X 10(-5) M against platelet aggregation induced by the alkylacetyl-GPC. Quantitatively, about 10(5) times higher concentrations of these inhibitors should be necessary to inhibit platelet aggregation induced by 1 X 10(-10) M 16:0 alkylacetyl-GPC. In fact, the contents of Inhibitors I and II, respectively, were approximately 10(5) times (4.7 X 10(-2) and 7.1 X 10(-2) mol/mol lipid-phosphorus of the original uterine phospholipids) than that of 16:0 alkylacetyl-GPC (1.4 X 10(-6) mol/mol lipid-phosphorus). The role of alkylacetyl-GPC in normal rat uterus is uncertain, but it coexists in situ with two kinds of endogenous inhibitors, choline containing lysoglycerophospholipids and sphingophospholipids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654606

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Quantitation by radioimmunoassay of PAF in human saliva.

Authors:  S J Cooney; M A Smal; B A Baldo
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

Authors:  F Lopez Diez; M L Nieto; S Fernandez-Gallardo; M A Gijon; M Sanchez Crespo
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

3.  Autoradiographic localization of platelet-activating factor (PAF) binding sites in the rabbit endometrium during the peri-implantation period.

Authors:  G B Kudolo; M Kasamo; M J Harper
Journal:  Cell Tissue Res       Date:  1991-08       Impact factor: 5.249

4.  Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation.

Authors:  D Tsoukatos; C A Demopoulos; A D Tselepis; M C Moschidis; A Donos; A Evangelou; J Benveniste
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

5.  Presence of platelet-activating factor in pyuria in humans.

Authors:  I Ikeda; M Oda; M Sakakura; K Yasunaga
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

6.  A specific, sensitive and high-capacity immunoassay for PAF.

Authors:  B A Baldo; M A Smal; A C McCaskill
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Inhibitor(s) of platelet-activating factor (PAF) in human saliva.

Authors:  M A Smal; B A Baldo
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Platelet-activating factor type activity in plasma from patients with septicemia and other diseases.

Authors:  H O Heuer; H Darius; H F Lohmann; J Meyer; M Schierenberg; N Treese
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.